Market-Moving News for June 21st
Market-Moving News for June 21st
SRPT: 45% | Sarepeta Therapeutics shares are trading higher after the company announced FDA approval of an expansion to the labeled indication for ELEVIDYS to include individuals with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene who are at least 4 years of age. Also, multiple firms raised their respective price targets on the stock.
SRPT：45% | 瑞普塔治疗股价上涨，该公司宣布FDA批准将ELEVIDYS的标签适应症扩展至Duchenne肌无力患者，这些患者年龄至少为4岁并确认DMD基因存在突变。此外，多家公司将其股票价格目标上调。
CLOV: 13% | Clover Health shares are trading higher following the purchase of 877,567 shares by a company director.
CLOV：13% | Clover Health的股价上涨，一位董事购买了877，567股。
NVNO: 16% | EnVVeno Medical shares are trading higher after the company reported interim venous ulcer healing data from the SAVVE U.E. pivotal trial for VenoValve, which will be presented at the Society for Vascular Surgery 2024 Annual Meeting.
NVNO: 16% | EnVVeno Medical的股价上涨，该公司报告了VenoValve的SAVVE UE关键试验中间期静脉溃疡愈合数据，将在2024年血管外科学会年会上展示。